Furiex Pharmaceuticals Lowered to Underperform at Zacks (FURX)
Furiex Pharmaceuticals (NASDAQ:FURX) was downgraded by Zacks from a “neutral” rating to an “underperform” rating in a report issued on Tuesday, Stock Ratings News reports. They currently have a $41.40 target price on the stock. Zacks‘ price objective points to a potential downside of 3.25% from the stock’s previous close.
Furiex Pharmaceuticals (NASDAQ:FURX) traded down 1.50% on Tuesday, hitting $42.79. The stock had a trading volume of 57,244 shares. Furiex Pharmaceuticals has a one year low of $17.50 and a one year high of $49.50. The stock’s 50-day moving average is $41.76 and its 200-day moving average is $38.44. The company’s market cap is $440.6 million.
Furiex Pharmaceuticals (NASDAQ:FURX) last announced its earnings results on Tuesday, August 6th. The company reported ($2.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.65) by $0.67. The company had revenue of $3.00 million for the quarter, compared to the consensus estimate of $11.94 million. The company’s revenue for the quarter was down 77.1% on a year-over-year basis. Analysts expect that Furiex Pharmaceuticals will post $-3.39 EPS for the current fiscal year.
Separately, analysts at Canaccord Genuity raised their price target on shares of Furiex Pharmaceuticals from $47.00 to $51.00 in a research note to investors on Wednesday, August 7th.
Furiex Pharmaceuticals, Inc is a drug development collaboration company. The Company’s product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.